Clinical Trial Update: Expanded Access to NanoPac

View source ↗

Summary

The expanded access program for NanoPac (paclitaxel nanoparticle formulation) has been discontinued and is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Carcinoma
• Prostate Cancer

Drugs mentioned

• NanoPac (paclitaxel nanoparticle formulation)

Snippet

Sponsor: NanOlogy, LLC | Conditions: Locally Advanced Pancreatic Carcinoma, Prostate Cancer | Status: NO_LONGER_AVAILABLE